Telemedicine Market Size, Share, Statistics & Trends Analysis Report By Component, By Application, By End User, and Segment Forecasts, 2021-2030

The global telemedicine market size was valued at $40,205.68 million in 2020 and is estimated to reach $431,823.81 million by 2030, growing at a CAGR of 25.90% from 2021 to 2030. Increased demand for radiological services as a result of the increased frequency of chronic conditions such as congestive heart failure, orthopedic injuries, and others are driving the telemedicine market forward. Furthermore, a large increase in government spending on the healthcare information (HCIT) sector, as well as a shift in key players' focus toward digital diagnostics innovation, is fueling the telemedicine market growth. 

Rising healthcare expenses, technical breakthroughs, greater remote patient monitoring, and the growing burden of chronic diseases are all driving the telemedicine market forward. Due to the pandemic, demand for healthcare services and technologies reached an all-time high. Furthermore, technology such as telemedicine, chatbots, and robots are being used to collect data, reassure the public, treat patients, make the diagnosis, and even prepare future vaccinations.

Furthermore, the rise in emerging prospects in developed countries would create additional potential chances for the telemedicine market to grow in the predicted years. The rapid improvements in healthcare, as well as the rising demand for virtual consultations by physicians and patients, would propel the telemedicine market forward and provide significant potential prospects for the market throughout the projection period.

Telemedicine is often regarded as the most adaptable technology for delivering health education, information, and care over long distances. Advanced patient-centered treatment and increased access to remote regions are now possible because of technological advancements. It also aids in the reduction of emergency room visits and hospitalization rates, this, in turn, is expected to drive telemedicine market growth. However, the industry faces a number of hurdles, including practitioner and patient opposition to technology, high implementation costs, and data privacy and security concerns. These variables may slow down the rate of growth to some extent.

Based on application, In 2020, the teledermatology segment was the leading revenue source, and it is expected to continue to be so throughout the projected period. The increased incidence of skin diseases is also contributing to the growth of the teledermatology market share.

Based on components, In 2020, the software sector dominated the market, and this trend is expected to continue during the forecast period. During the COVID-19, the adoption of telehealth, telemedicine, and telemedicine-based consultations increased.

Based on end-user, In 2020, the healthcare providers segment led the market, and it is expected to continue to do so throughout the forecast period. The growth of this category is likely to be fueled by increased demand for mobile technology, patient adoption of home care, and a reduction in hospital visits.

Due to increased healthcare awareness combined with cloud-based technology acceptance over the forecast years, North America accounted for a large proportion of the telemedicine market in 2020 and is expected to maintain its dominance during the forecast period. Furthermore, thanks to continuous R&D endeavors, a developed region such as North America has accounted for the largest revenue share in the worldwide business. Furthermore, the market's expansion is aided by the presence of key players in the region. However, due to the rising demand for healthcare support, particularly in rural regions, Asia-Pacific is predicted to have the greatest CAGR from 2021 to 2030. Furthermore, in the near future, innovation and progress in the field of telecommunications are expected to boost growth in this region.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the telemedicine market, and the current trends and future estimations to elucidate the imminent investment pockets.
• It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
• Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

• Teleradiology
• Telepsychiatry
• Telepathology
• Teledermatology
• Telecardiology
• Other Applications 

Telemedicine Market by Component

• Software
• Hardware
• Services

Telemedicine Market by End-User

• Healthcare Providers
• Software
• Hardware
• Services
• Payers
• Software
• Hardware
• Services
• Healthcare Consumers
• Software
• Hardware
• Services
• Other End Users
• Software
• Hardware
• Services

Major Players in the Telemedicine Market

• Koninklijke Philips N.V. 
• Medtronic 
• GE Healthcare
• Cerner Corporation
• Siemens Healthineers
• Cisco Systems, Inc.
• Teladoc Health Inc.
• American Well 
• AMC Health
• MDLive

Table of Content

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in government investments and R&D expenditure in pharmaceutical & biotechnology companies
3.5.1.2.Surge in usage of synthesized oligonucleotides in molecular diagnostics and clinical applications
3.5.1.3.Rise in demand for high end customized oligos and upgradation in purification

3.5.2.Restraints

3.5.2.1.Complexities associated with therapeutic oligos
3.5.2.2.Challenging delivery of oligonucleotide drugs to specific targets

3.5.3.Opportunities

3.5.3.1.Growth opportunities in emerging economies
3.5.3.2.Growing focus on personalized medicine

3.5.4.Impact analysis

3.6.COVID-19 impact analysis on the oligonucleotide synthesis market

CHAPTER 4:OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Oligonucleotide-based drugs

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Synthesized oligonucleotides

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Reagents

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

4.5.Equipment

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country

CHAPTER 5:OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Therapeutic applications

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.2.3.Market size and forecast, by Product

5.3.Research applications

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.3.3.Market size and forecast, by Product

5.4.Diagnostic applications

5.4.1.Market size and forecast
5.4.2.Market analysis, by country
5.4.3.Market size and forecast, by Product

CHAPTER 6:OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END-USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Pharmaceutical & biotechnology companies

6.3.1.Market size and forecast
6.3.2.Market analysis, by country

6.4.Diagnostic laboratories

6.4.1.Market size and forecast
6.4.2.Market analysis, by country

6.5.CROs and CMOs

6.5.1.Market size and forecast
6.5.2.Market analysis, by country

6.6.Academic research institutes

6.6.1.Market size and forecast
6.6.2.Market analysis, by country

CHAPTER 7:OLIGONUCLEOTIDE SYNTHESIS, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. oligonucleotide synthesis market, by product
7.2.2.1.2.U.S. oligonucleotide synthesis market, by application
7.2.2.1.3.U.S. oligonucleotide synthesis market, by end user

7.2.2.2.Canada

7.2.2.2.1.Canada oligonucleotide synthesis, by product
7.2.2.2.2.Canada oligonucleotide synthesis market, by application
7.2.2.2.3.Canada oligonucleotide synthesis market, by end user

7.2.2.3.Mexico

7.2.2.3.1.Mexico oligonucleotide synthesis market, by product
7.2.2.3.2.Mexico oligonucleotide synthesis market, by application
7.2.2.3.3.Mexico oligonucleotide synthesis market, by end user

7.2.3.North America market size and forecast, by product
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany oligonucleotide synthesis market, by product
7.3.2.1.2.Germany oligonucleotide synthesis market, by application
7.3.2.1.3.Germany oligonucleotide synthesis market, by end user

7.3.2.2.France

7.3.2.2.1.France oligonucleotide synthesis market, by product
7.3.2.2.2.France oligonucleotide synthesis market, by application
7.3.2.2.3.France oligonucleotide synthesis market, by end user

7.3.2.3.UK

7.3.2.3.1.UK oligonucleotide synthesis market, by product
7.3.2.3.2.UK oligonucleotide synthesis market, by application
7.3.2.3.3.UK oligonucleotide synthesis market, by end user

7.3.2.4.Italy

7.3.2.4.1.Italy oligonucleotide synthesis market, by product
7.3.2.4.2.Italy oligonucleotide synthesis market, by application
7.3.2.4.3.Italy oligonucleotide synthesis market, by end user

7.3.2.5.Spain

7.3.2.5.1.Spain oligonucleotide synthesis market, by product
7.3.2.5.2.Spain oligonucleotide synthesis market, by application
7.3.2.5.3.Spain oligonucleotide synthesis market, by end user

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe oligonucleotide synthesis market, by product
7.3.2.6.2.Rest of Europe oligonucleotide synthesis market, by application
7.3.2.6.3.Rest of Europe oligonucleotide synthesis market, by end user

7.3.3.Europe market size and forecast, by product
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan

7.4.2.1.1.Japan Oligonucleotide synthesis market, by product
7.4.2.1.2.Japan oligonucleotide synthesis market, by application
7.4.2.1.3.Japan oligonucleotide synthesis market, by end user

7.4.2.2.China

7.4.2.2.1.China Oligonucleotide synthesis market, by product
7.4.2.2.2.China oligonucleotide synthesis market, by application
7.4.2.2.3.China Oligonucleotide synthesis market, by end user

7.4.2.3.Australia

7.4.2.3.1.Australia oligonucleotide synthesis market, by product
7.4.2.3.2.Australia oligonucleotide synthesis market, by application
7.4.2.3.3.Australia oligonucleotide synthesis market, by end user

7.4.2.4.India

7.4.2.4.1.India oligonucleotide synthesis market, by product
7.4.2.4.2.India oligonucleotide synthesis market, by application
7.4.2.4.3.India oligonucleotide synthesis market, by end user

7.4.2.5.South Korea

7.4.2.5.1.South Korea oligonucleotide synthesis market, by product
7.4.2.5.2.South Korea oligonucleotide synthesis market, by application
7.4.2.5.3.South Korea Oligonucleotide synthesis market, by end user

7.4.2.6.Rest of Asia-Pacific

7.4.2.6.1.Rest of Asia-Pacific oligonucleotide synthesis market, by product
7.4.2.6.2.Rest of Asia-Pacific oligonucleotide synthesis market, by application
7.4.2.6.3.Rest of Asia-Pacific oligonucleotide synthesis market, by end user

7.4.3.Asia-Pacific market size and forecast, by product
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil oligonucleotide synthesis market, by product
7.5.2.1.2.Brazil oligonucleotide synthesis market, by application
7.5.2.1.3.Brazil oligonucleotide synthesis market, by end user

7.5.2.2.Saudi Arabia

7.5.2.2.1.Saudi Arabia oligonucleotide synthesis market, by product
7.5.2.2.2.Saudi Arabia oligonucleotide synthesis market, by application
7.5.2.2.3.Saudi Arabia oligonucleotide synthesis market, by end user

7.5.2.3.South Africa

7.5.2.3.1.South Africa oligonucleotide synthesis market, by product
7.5.2.3.2.South Africa oligonucleotide synthesis market, by application
7.5.2.3.3.South Africa oligonucleotide synthesis market, by end user

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA oligonucleotide synthesis market, by product
7.5.2.4.2.Rest of LAMEA oligonucleotide synthesis market, by application
7.5.2.4.3.Rest of LAMEA oligonucleotide synthesis market, by end user

7.5.3.LAMEA market size and forecast, by product
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.ALNYLAM PHARMACEUTICALS, INC.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.BIOGEN LIMITED

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.CINVEN

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio

8.4.DANAHER CORPORATION

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.EUROFINS SCIENTIFIC

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.IONIS PHARMACEUTICALS, INC.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.KANEKA CORPORATION

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.MERCK KGAA

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.SAREPTA THERAPEUTICS, INC.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.THERMO FISHER SCIENTIFIC, INC.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

List of Tables & Figure

Table 01.Oligonucleotide Synthesis Market, By Product, 2020-2030 ($Billion)

Table 02.Oligonucleotide Synthesis Market For Oligonucleotide-based Drugs, By Region, 2020-2030 ($Billion)

Table 03.Oligonucleotide Synthesis Market For Synthesized Oligonucleotides, By Region, 2020-2030 ($Billion)

Table 04.Oligonucleotide Synthesis Market For Reagents, By Region, 2020-2030 ($Billion)

Table 05.Oligonucleotide Synthesis Market For Equipment, By Region, 2020-2030 ($Billion)

Table 06.Oligonucleotide Synthesis Market, By Application, 2020-2030($Billion)

Table 07.Oligonucleotide Synthesis Market For Research Applications, By Region, 2020-2030($Billion)

Table 08.Oligonucleotide Synthesis Market For Research Applications, By Product, 2020-2030($Billion)

Table 09.Oligonucleotide Synthesis Market For Research Applications, By Region, 2020-2030($Billion)

Table 10.Oligonucleotide Synthesis Market For Research Applications, By Product, 2020-2030($Billion)

Table 11.Oligonucleotide Synthesis Market For Diagnostic Applications, By Region, 2020-2030($Billion)

Table 12.Oligonucleotide Synthesis Market For Diagnostics Applications, By Product, 2020-2030($Billion)

Table 13.Oligonucleotide Synthesis Market, By End User, 2020-2030($Million)

Table 14.Oligonucleotide Synthesis Market For Hospitals, By Region, 2020-2030($Million)

Table 15.Oligonucleotide Synthesis Market For Pharmaceutical & Biotechnology Companies, By Region, 2020-2030($Million)

Table 16.Oligonucleotide Synthesis Market For Diagnostic Laboratories, By Region, 2020-2030($Million)

Table 17.Oligonucleotide Synthesis Market For Cros And Cmos, By Region, 2020-2030($Million)

Table 18.Oligonucleotide Synthesis Market For Academic Research Institutes, By Region, 2020-2030($Million)

Table 19.Oligonucleotide Synthesis Market, By Region, 2020-2030($Million)

Table 20.North America Oligonucleotide Synthesis Market, By Country, 2020-2030($Million)

Table 21.U.S. Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 22.U.S. Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 23.U.S. Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 24.Canada Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 25.Canada Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 26.Canada Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 27.Mexico Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 28.Mexico Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 29.Mexico Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 30.North America Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 31.North America Oligonucleotide Synthesis Market , By Application, 2020-2030

Table 32.North America Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 33.Europe Oligonucleotide Synthesis Market, By Country, 2020-2030($Million)

Table 34.Germany Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 35.Germany Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 36.Germany Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 37.France Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 38.France Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 39.France Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 40.Uk Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 41.Uk Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 42.Uk Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 43.Italy Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 44.Italy Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 45.Italy Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 46.Spain Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 47.Spain Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 48.Spain Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 49.Rest Of Europe Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 50.Rest Of Europe Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 51.Rest Of Europe Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 52.Europe Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 53.Europe Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 54.Europe Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 55.Asia-pacific Oligonucleotide Synthesis Market, By Country, 2020-2030($Million)

Table 56.Japan Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 57.Japan Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 58.Japan Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 59.China Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 60.China Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 61.China Oligonucleotide Synthesis, By End User, 2020-2030

Table 62.Australia Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 63.Australia Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 64.Australia Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 65.India Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 66.India Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 67.India Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 68.South Korea Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 69.South Korea Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 70.South Korea Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 71.Rest Of Asia-pacific Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 72.Rest Of Asia-pacific Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 73.Rest Of Asia-pacific Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 74.Asia-pacific Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 75.Asia-pacific Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 76.Asia-pacific Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 77.Lamea Oligonucleotide Synthesis Market, By Country, 2020-2030($Million)

Table 78.Brazil Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 79.Brazil Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 80.Brazil Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 81.Saudi Arabia Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 82.Saudi Arabia Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 83.Saudi Arabia Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 84.South Africa Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 85.South Africa Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 86.South Africa Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 87.Rest Of Lamea Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 88.Rest Of Lamea Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 89.Rest Of Lamea Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 90.Lamea Oligonucleotide Synthesis Market, By Product, 2020-2030

Table 91.Lamea Oligonucleotide Synthesis Market, By Application, 2020-2030

Table 92.Lamea Oligonucleotide Synthesis Market, By End User, 2020-2030

Table 93.Alnylam: Company Snapshot

Table 94.Alnylam: Operating Business Segments

Table 95.Alnylam: Product Portfolio

Table 96.Alnylam: Key Developments

Table 97.Biogen: Company Snapshot

Table 98.Biogen: Operating Segments

Table 99.Biogen: Product Portfolio

Table 100.Biogen: Key Developments

Table 101.Cinven: Company Snapshot

Table 102.Cinven: Operating Segments

Table 103.Cinven: Product Portfolio

Table 104.Danaher: Company Snapshot

Table 105.Danaher: Product Segments

Table 106.Danaher: Product Portfolio

Table 107.Danaher: Key Developments

Table 108.Eurofins: Company Snapshot

Table 109.Eurofins: Product Portfolio

Table 110.Eurofins: Key Developments

Table 111.Ionis: Company Snapshot

Table 112.Ionis: Operating Business Segments

Table 113.Ionis: Product Portfolio

Table 114.Ionis: Key Developments

Table 115.Kaneka: Company Snapshot

Table 116.Kaneka: Operating Segments

Table 117.Kaneka: Product Portfolio

Table 118.Kaneka: Key Developments

Table 119.Merck: Company Snapshot

Table 120.Merck: Operating Segments

Table 121.Merck: Product Portfolio

Table 122.Merck: Key Developments

Table 123.Sarepta: Company Snapshot

Table 124.Sarepta: Operating Business Segments

Table 125.Sarepta: Product Portfolio

Table 126.Sarepta: Key Developments

Table 127.Thermo Fisher: Company Snapshot

Table 128.Thermo Fisher: Operating Segments

Table 129.Thermo Fisher: Product Portfolio

Table 130.Thermo Fisher: Key Developments

List Of Figures

Figure 01.Oligonucleotide Synthesis Market Segmentation

Figure 02.Top Investment Pockets

Figure 03.Top Winning Strategies, By Year, 2018-2021

Figure 04.Top Winning Strategies, By Development, 2018-2021

Figure 05.Top Winning Strategies, By Company, 2018-2021

Figure 06.Moderate Bargaining Power Of Suppliers

Figure 07.Moderate Bargaining Power Of Buyers

Figure 08.Moderate Threat Of Substitutes

Figure 09.Moderate Threat Of New Entrants

Figure 10.Moderate Intensity Of Rivalry

Figure 11.Top Player Positioning, 2020

Figure 12.Impact Analysis

Figure 13.Comparative Analysis Of Oligonucleotide Synthesis Market For Oligonucleotide-based Drugs, By Country, 2020 & 2030 ($Billion)

Figure 14.Comparative Analysis Of Oligonucleotide Synthesis Market For Synthesized Oligonucleotides, By Country, 2020 & 2030 ($Billion)

Figure 15.Comparative Analysis Of Oligonucleotide Synthesis Market For Reagents, By Country, 2020 & 2030 ($Billion)

Figure 16.Comparative Analysis Of Oligonucleotide Synthesis Market For Equipment, By Country, 2020 & 2030 ($Billion)

Figure 17.Comparative Analysis Of Oligonucleotide Synthesis Market For Research Applications, By Country, 2020 & 2030 ($Billion)

Figure 18.Comparative Analysis Of Oligonucleotide Synthesis Market For Research Applications, By Country, 2020 & 2030 ($Billion)

Figure 19.Comparative Analysis Of Oligonucleotide Synthesis Market Diagnostic Applications, By Country, 2020 & 2030 ($Billion)

Figure 20.Comparative Analysis Of Oligonucleotide Synthesis Market For Hospitals, By Country, 2020 & 2030 ($Million)

Figure 21.Comparative Analysis Of Oligonucleotide Synthesis Market For Pharmaceutical & Biotechnology Companies, By Country, 2020 & 2030 ($Million)

Figure 22.Comparative Analysis Of Oligonucleotide Synthesis Market For Diagnostic Laboratories,  By Country, 2020 & 2030 ($Million)

Figure 23.Comparative Analysis Of Oligonucleotide Synthesis Market For Cros And Cmos, By Country,  2020 & 2030 ($Million)

Figure 24.Comparative Analysis Of Oligonucleotide Synthesis Market For Academic Research Institutes, By Country, 2020 & 2030 ($Million)

Figure 25.Alnylam: Net Sales, 2018–2020 ($Million)

Figure 26.Biogen: Net Sales, 2018–2020 ($Million)

Figure 27.Danaher: Net Sales, 2018–2020 ($Million)

Figure 28.Danaher: Revenue Share By Segment, 2020 (%)

Figure 29.Danaher: Revenue Share By Region, 2020(%)

Figure 30.Eurofins: Net Sales, 2018–2020 ($Million)

Figure 31.Eurofins: Revenue Share By Region, 2020 (%)

Figure 32.Ionis: Net Sales, 2018–2020 ($Million)

Figure 33.Ionis: Revenue Share By Segment, 2020 (%)

Figure 34.Kaneka: Net Sales, 2018–2020 ($Million)

Figure 35.Kaneka: Revenue Share By Segment, 2020 (%)

Figure 36.Kaneka: Revenue Share By Region, 2020(%)

Figure 37.Merck: Net Sales, 2018–2020 ($Million)

Figure 38.Merck: Revenue Share By Segment, 2020 (%)

Figure 39.Merck: Revenue Share By Region, 2020(%)

Figure 40.Sarepta: Net Sales, 2018–2020 ($Million)

Figure 41.Thermo Fisher: Net Sales, 2018–2020 ($Million)

Figure 42.Thermo Fisher: Revenue Share By Segment, 2020 (%)

Figure 43.Thermo Fisher: Revenue Share By Region, 2020(%)